{"product_id":"solidstate-properties-of-pharmaceutical-materials-9781118145302","title":"SolidState Properties of Pharmaceutical Materials","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003ePresents a detailed discussion of important solid-state properties, methods, and applications of solid-state analysis\u003cbr\u003e \u003cul\u003e \u003cli\u003eIllustrates the various phases or forms that solids can assume and discussesvarious issues related to the relative stability of solid forms and tendencies to undergo transformation\u003c\/li\u003e \u003cli\u003eCovers key methods of solid state analysis including X-ray powder diffraction, thermal analysis, microscopy, spectroscopy, and solid state NMR\u003c\/li\u003e \u003cli\u003eReviews critical physical attributes of pharmaceutical materials, mainly related to drug substances, including particle size\/surface area, hygroscopicity, mechanical properties, solubility, and physical and chemical stability\u003c\/li\u003e \u003cli\u003eShowcases the application of solid state material science in rational selection of drug solid forms, analysis of various solid forms within drug substance and the drug product, and pharmaceutical product development\u003c\/li\u003e \u003cli\u003eIntroduces appropriate manufacturing and control procedures using\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003ePreface xi\u003c\/p\u003e \u003cp\u003eAcknowledgments xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Solid-State Properties and Pharmaceutical Development 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction, 1\u003c\/p\u003e \u003cp\u003e1.2 Solid-State Forms, 1\u003c\/p\u003e \u003cp\u003e1.3 ICH Q6A Decision Trees, 6\u003c\/p\u003e \u003cp\u003e1.4 “Big Questions” for Drug Development, 6\u003c\/p\u003e \u003cp\u003e1.5 Accelerating Drug Development, 9\u003c\/p\u003e \u003cp\u003e1.6 Solid-State Chemistry in Preformulation and Formulation, 11\u003c\/p\u003e \u003cp\u003e1.7 Learning Before Doing and Quality by Design, 14\u003c\/p\u003e \u003cp\u003e1.8 Performance and Stability in Pharmaceutical Development, 17\u003c\/p\u003e \u003cp\u003e1.9 Moisture Uptake, 18\u003c\/p\u003e \u003cp\u003e1.10 Solid-State Reactions, 19\u003c\/p\u003e \u003cp\u003e1.11 Noninteracting Formulations: Physical Characterizations, 19\u003c\/p\u003e \u003cp\u003eReferences, 20\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Polymorphs 22\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction, 22\u003c\/p\u003e \u003cp\u003e2.2 How are Polymorphs Formed?, 22\u003c\/p\u003e \u003cp\u003e2.3 Structural Aspect of Polymorphs, 23\u003c\/p\u003e \u003cp\u003e2.4 Physical, Chemical, and Mechanical Properties, 24\u003c\/p\u003e \u003cp\u003e2.5 Thermodynamic Stability of Polymorphs, 27\u003c\/p\u003e \u003cp\u003e2.6 Polymorph Conversion, 32\u003c\/p\u003e \u003cp\u003e2.7 Control of Polymorphs, 34\u003c\/p\u003e \u003cp\u003e2.8 Polymorph Screening, 35\u003c\/p\u003e \u003cp\u003e2.9 Polymorph Prediction, 36\u003c\/p\u003e \u003cp\u003eReferences, 36\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Solvates and Hydrates 38\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction, 38\u003c\/p\u003e \u003cp\u003e3.2 Pharmaceutical Importance of Hydrates, 38\u003c\/p\u003e \u003cp\u003e3.3 Classification of Pharmaceutical Hydrates, 40\u003c\/p\u003e \u003cp\u003e3.4 Water Activity, 42\u003c\/p\u003e \u003cp\u003e3.5 Stoichiometric Hydrates, 43\u003c\/p\u003e \u003cp\u003e3.6 Nonstoichiometric Hydrates, 44\u003c\/p\u003e \u003cp\u003e3.7 Hydration\/Dehydration, 45\u003c\/p\u003e \u003cp\u003e3.8 Preparation and Characterization of Hydrates and Solvates, 45\u003c\/p\u003e \u003cp\u003eReferences, 46\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Pharmaceutical Salts 48\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction, 48\u003c\/p\u003e \u003cp\u003e4.2 Importance of Pharmaceutical Salts, 48\u003c\/p\u003e \u003cp\u003e4.3 Weak Acid, Weak Base, and Salt, 49\u003c\/p\u003e \u003cp\u003e4.4 pH-Solubility Profiles of Ionizable Compounds, 51\u003c\/p\u003e \u003cp\u003e4.5 Solubility, Dissolution, and Bioavailability of Pharmaceutical Salts, 53\u003c\/p\u003e \u003cp\u003e4.6 Physical Stability of Pharmaceutical Salts, 56\u003c\/p\u003e \u003cp\u003e4.7 Strategies for Salt Selection, 57\u003c\/p\u003e \u003cp\u003eReferences, 59\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Pharmaceutical Cocrystals 60\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction, 60\u003c\/p\u003e \u003cp\u003e5.2 Cocrystals and Crystal Engineering, 60\u003c\/p\u003e \u003cp\u003e5.3 Solubility Phase Diagrams for Cocrystals, 62\u003c\/p\u003e \u003cp\u003e5.4 Preparation of Cocrystals, 63\u003c\/p\u003e \u003cp\u003e5.5 Dissolution and Bioavailability of Cocrystals, 64\u003c\/p\u003e \u003cp\u003e5.6 Comparison of Pharmaceutical Salts and Cocrystals, 66\u003c\/p\u003e \u003cp\u003eReferences, 68\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Amorphous Solids 69\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction, 69\u003c\/p\u003e \u003cp\u003e6.2 The Formation of Amorphous Solids, 70\u003c\/p\u003e \u003cp\u003e6.3 Methods of Preparing Amorphous Solids, 71\u003c\/p\u003e \u003cp\u003e6.4 The Glass Transition Temperature, 72\u003c\/p\u003e \u003cp\u003e6.5 Structural Features of Amorphous Solids, 75\u003c\/p\u003e \u003cp\u003e6.6 Molecular Mobility, 77\u003c\/p\u003e \u003cp\u003e6.7 Mixtures of Amorphous Solids, 84\u003c\/p\u003e \u003cp\u003eReferences, 87\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Crystal Mesophases and Nanocrystals 89\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction, 89\u003c\/p\u003e \u003cp\u003e7.2 Overview of Crystal Mesophases, 89\u003c\/p\u003e \u003cp\u003e7.3 Liquid Crystals, 90\u003c\/p\u003e \u003cp\u003e7.4 Conformationally Disordered (Condis) Crystals, 95\u003c\/p\u003e \u003cp\u003e7.5 Plastic Crystals, 95\u003c\/p\u003e \u003cp\u003e7.6 Nanocrystals, 96\u003c\/p\u003e \u003cp\u003eReferences, 97\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 X-Ray Crystallography and Crystal Packing Analysis 99\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction, 99\u003c\/p\u003e \u003cp\u003e8.2 Crystals, 99\u003c\/p\u003e \u003cp\u003e8.3 Miller Indices and Crystal Faces, 99\u003c\/p\u003e \u003cp\u003e8.4 Determination of the Miller Indices of the Faces of a Crystal, 101\u003c\/p\u003e \u003cp\u003e8.5 Determination of Crystal Structure, 103\u003c\/p\u003e \u003cp\u003eReferences, 106\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 X-Ray Powder Diffraction 107\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction, 107\u003c\/p\u003e \u003cp\u003e9.2 X-Ray Powder Diffraction of Crystalline Materials, 107\u003c\/p\u003e \u003cp\u003e9.3 Qualitative Analysis of Crystalline Materials, 109\u003c\/p\u003e \u003cp\u003e9.4 Phase Transformations, 110\u003c\/p\u003e \u003cp\u003e9.5 Quantitative Phase Analysis Using XRPD, 111\u003c\/p\u003e \u003cp\u003e9.6 Solving Crystal Structures Using Powder X-Ray Diffraction, 114\u003c\/p\u003e \u003cp\u003e9.7 X-Ray Diffraction of Amorphous and Crystal Mesophase Forms, 116\u003c\/p\u003e \u003cp\u003e9.8 Pair Distribution Function, 117\u003c\/p\u003e \u003cp\u003e9.9 X-Ray Diffractometers, 119\u003c\/p\u003e \u003cp\u003e9.10 Variable Temperature XRPD, 121\u003c\/p\u003e \u003cp\u003eReferences, 122\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Differential Scanning Calorimetry and Thermogravimetric Analysis 124\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction, 124\u003c\/p\u003e \u003cp\u003e10.2 The Basics of Differential Scanning Calorimetry, 124\u003c\/p\u003e \u003cp\u003e10.3 Thermal Transitions of Pharmaceutical Materials, 125\u003c\/p\u003e \u003cp\u003e10.4 DSC Instrumentation, 128\u003c\/p\u003e \u003cp\u003e10.5 Thermogravimetric Analysis, 132\u003c\/p\u003e \u003cp\u003e10.6 Operating a TGA Instrument, 133\u003c\/p\u003e \u003cp\u003e10.7 Evolved Gas Analysis, 133\u003c\/p\u003e \u003cp\u003e10.8 Applications of DSC and TGA, 134\u003c\/p\u003e \u003cp\u003e10.9 Summary of Using DSC and TGA, 139\u003c\/p\u003e \u003cp\u003eReferences, 140\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Microscopy 142\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction, 142\u003c\/p\u003e \u003cp\u003e11.2 Light Microscopy, 142\u003c\/p\u003e \u003cp\u003e11.3 Polarized Light Microscopy, 144\u003c\/p\u003e \u003cp\u003e11.4 Thermal Microscopy, 144\u003c\/p\u003e \u003cp\u003e11.5 Functionality of the Light Microscope, 145\u003c\/p\u003e \u003cp\u003e11.6 Digital Microscope, 146\u003c\/p\u003e \u003cp\u003e11.7 Application of Light Microscopy to Pharmaceutical Materials, 146\u003c\/p\u003e \u003cp\u003e11.8 Scanning Electron Microscope, 153\u003c\/p\u003e \u003cp\u003e11.9 Environmental Scanning Electron Microscopy, 155\u003c\/p\u003e \u003cp\u003e11.10 Atomic Force Microscopy, 155\u003c\/p\u003e \u003cp\u003eReferences, 157\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Vibrational Spectroscopy 159\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction, 159\u003c\/p\u003e \u003cp\u003e12.2 The Nature of Molecular Vibrations, 160\u003c\/p\u003e \u003cp\u003e12.3 Fourier Transformed Infrared Spectroscopy, 161\u003c\/p\u003e \u003cp\u003e12.4 Material Characterization by FT-IR Spectroscopy, 162\u003c\/p\u003e \u003cp\u003e12.5 FT-IR Instrumentation, 164\u003c\/p\u003e \u003cp\u003e12.6 Diffuse Reflectance FT-IR, 165\u003c\/p\u003e \u003cp\u003e12.7 Attenuated Total Reflectance FT-IR, 166\u003c\/p\u003e \u003cp\u003e12.8 FT-IR Microscopy, 167\u003c\/p\u003e \u003cp\u003e12.9 Near Infrared Spectroscopy, 168\u003c\/p\u003e \u003cp\u003e12.10 Raman Spectroscopy, 170\u003c\/p\u003e \u003cp\u003e12.11 Raman Instrumentation and Sampling, 171\u003c\/p\u003e \u003cp\u003e12.12 Raman Microscope, 173\u003c\/p\u003e \u003cp\u003e12.13 Terahertz Spectroscopy, 175\u003c\/p\u003e \u003cp\u003e12.14 Comparison of FT-IR, NIR, Raman, and Terahertz Spectroscopy, 176\u003c\/p\u003e \u003cp\u003eReferences, 178\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Solid-State NMR Spectroscopy 180\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction, 180\u003c\/p\u003e \u003cp\u003e13.2 An Overview of Solid-State 13C CP\/MAS NMR Spectroscopy, 180\u003c\/p\u003e \u003cp\u003e13.3 Solid-State NMR Studies of Pharmaceuticals, 185\u003c\/p\u003e \u003cp\u003e13.4 Phase Identification in Dosage Forms, 186\u003c\/p\u003e \u003cp\u003e13.5 Other Basic Solid-State NMR Experiments Useful for Pharmaceutical Analysis, 189\u003c\/p\u003e \u003cp\u003e13.6 Determination of the Domain Structure of Amorphous Dispersions Using\u003c\/p\u003e \u003cp\u003eSolid-State NMR, 192\u003c\/p\u003e \u003cp\u003eReferences, 196\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Particle and Powder Analysis 197\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction, 197\u003c\/p\u003e \u003cp\u003e14.2 Particles in Pharmaceutical Systems, 197\u003c\/p\u003e \u003cp\u003e14.3 Particle Size and Shape, 199\u003c\/p\u003e \u003cp\u003e14.4 Particle Size Distribution, 200\u003c\/p\u003e \u003cp\u003e14.5 Dynamic Light Scattering, 202\u003c\/p\u003e \u003cp\u003e14.6 Zeta Potential, 203\u003c\/p\u003e \u003cp\u003e14.7 Laser Diffraction, 205\u003c\/p\u003e \u003cp\u003e14.8 Dynamic Image Analysis, 206\u003c\/p\u003e \u003cp\u003e14.9 Sieve Analysis, 208\u003c\/p\u003e \u003cp\u003e14.10 Bulk Properties of Pharmaceutical Particulates and Powders, 208\u003c\/p\u003e \u003cp\u003e14.11 Surface Area Measurement, 209\u003c\/p\u003e \u003cp\u003eReferences, 211\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Hygroscopic Properties of Solids 213\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction, 213\u003c\/p\u003e \u003cp\u003e15.2 Water Vapor Sorption–Desorption, 214\u003c\/p\u003e \u003cp\u003e15.3 Water Vapor Sorption Isotherms, Relative Humidity, and Water Activity, 214\u003c\/p\u003e \u003cp\u003e15.4 Measurement of Water Content and Water Vapor Sorption\/Desorption Isotherms, 216\u003c\/p\u003e \u003cp\u003e15.5 Modes of Water Vapor Sorption, 218\u003c\/p\u003e \u003cp\u003eReferences, 229\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Mechanical Properties of Pharmaceutical Materials 231\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction, 231\u003c\/p\u003e \u003cp\u003e16.2 Stress and Strain, 231\u003c\/p\u003e \u003cp\u003e16.3 Elasticity, 232\u003c\/p\u003e \u003cp\u003e16.4 Plasticity, 233\u003c\/p\u003e \u003cp\u003e16.5 Viscoelasticity, 234\u003c\/p\u003e \u003cp\u003e16.6 Brittleness, 235\u003c\/p\u003e \u003cp\u003e16.7 Hardness, 236\u003c\/p\u003e \u003cp\u003e16.8 Powder Compression, 237\u003c\/p\u003e \u003cp\u003e16.9 Powder Compression Models and Compressibility, 238\u003c\/p\u003e \u003cp\u003e16.10 Compactibility and Tensile Strength, 239\u003c\/p\u003e \u003cp\u003e16.11 Effect of Solid Form on Mechanical Properties, 239\u003c\/p\u003e \u003cp\u003e16.12 Effect of Moisture on Mechanical Properties, 242\u003c\/p\u003e \u003cp\u003e16.13 Methods for Testing Mechanical Properties: Beam Bending, 243\u003c\/p\u003e \u003cp\u003e16.14 Nanoindentation, 246\u003c\/p\u003e \u003cp\u003eReferences, 247\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Solubility and Dissolution 249\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e17.1 Introduction, 249\u003c\/p\u003e \u003cp\u003e17.2 Principle Concepts Associated with Solubility, 249\u003c\/p\u003e \u003cp\u003e17.3 Prediction of Aqueous Drug Solubility, 250\u003c\/p\u003e \u003cp\u003e17.4 Solubility of Pharmaceutical Solid Forms, 252\u003c\/p\u003e \u003cp\u003e17.5 Solubility Determination Using the Shake Flask Method, 253\u003c\/p\u003e \u003cp\u003e17.6 High Throughput Screening of Solubility, 254\u003c\/p\u003e \u003cp\u003e17.7 Solubility Measurement of Metastable Forms, 255\u003c\/p\u003e \u003cp\u003e17.8 Kinetic Solubility Measurement, 256\u003c\/p\u003e \u003cp\u003e17.9 Solubility Determination of Drugs in Polymer Matrices, 256\u003c\/p\u003e \u003cp\u003e17.10 Dissolution Testing, 257\u003c\/p\u003e \u003cp\u003e17.11 Nonsink Dissolution Test, 260\u003c\/p\u003e \u003cp\u003e17.12 Intrinsic Dissolution Studies, 262\u003c\/p\u003e \u003cp\u003eReferences, 263\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Physical Stability of Solids 265\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e18.1 Introduction, 265\u003c\/p\u003e \u003cp\u003e18.2 Underlying Basis for Physical Instability in Pharmaceutical Systems, 266\u003c\/p\u003e \u003cp\u003e18.3 Disorder in Crystals, 267\u003c\/p\u003e \u003cp\u003e18.4 Examples of the Role of Process-Induced Disorder in Solid-State Physical Instability in Pharmaceutical Systems, 274\u003c\/p\u003e \u003cp\u003e18.5 Considerations in Evaluating Solid-State Physical Stability, 276\u003c\/p\u003e \u003cp\u003eReferences, 277\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Chemical Stability of Solids 279\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e19.1 Introduction, 279\u003c\/p\u003e \u003cp\u003e19.2 Examples of Chemical Reactivity in the Solid State, 279\u003c\/p\u003e \u003cp\u003e19.3 Some General Principles that Establish the Rate of Chemical Reactions in Solution, 282\u003c\/p\u003e \u003cp\u003e19.4 The Role of Crystal Defects in Solid-State Reactions, 286\u003c\/p\u003e \u003cp\u003e19.5 Chemical Reactivity in the Amorphous Solid State, 290\u003c\/p\u003e \u003cp\u003e19.6 Chemical Reactivity and Processed-Induced Disorder, 292\u003c\/p\u003e \u003cp\u003e19.7 The Effects of Residual Water on Solid-State Chemical Reactivity, 294\u003c\/p\u003e \u003cp\u003e19.8 Drug–Excipient Interactions, 298\u003c\/p\u003e \u003cp\u003e19.9 Summary, 300\u003c\/p\u003e \u003cp\u003eReferences, 300\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Solid-State Properties of Proteins 302\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e20.1 Introduction, 302\u003c\/p\u003e \u003cp\u003e20.2 Solution Properties of Proteins, 302\u003c\/p\u003e \u003cp\u003e20.3 Amorphous Properties of Proteins, 306\u003c\/p\u003e \u003cp\u003e20.4 Crystalline Properties of Proteins, 307\u003c\/p\u003e \u003cp\u003e20.5 Local Molecular Motions and the Dynamical Transitional Temperature, Td, 308\u003c\/p\u003e \u003cp\u003e20.6 Solid-State Physical and Chemical Stability of Proteins, 310\u003c\/p\u003e \u003cp\u003e20.7 Cryoprotection and Lyoprotection, 311\u003c\/p\u003e \u003cp\u003eReferences, 311\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Form Selection of Active Pharmaceutical Ingredients 313\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e21.1 Introduction, 313\u003c\/p\u003e \u003cp\u003e21.2 Form Selection, 313\u003c\/p\u003e \u003cp\u003e21.3 Amorphous form Screening, 315\u003c\/p\u003e \u003cp\u003e21.4 Salt Selection, 316\u003c\/p\u003e \u003cp\u003e21.5 Cocrystal Screening, 318\u003c\/p\u003e \u003cp\u003e21.6 Polymorph Screening, 320\u003c\/p\u003e \u003cp\u003e21.7 Slurrying, 321\u003c\/p\u003e \u003cp\u003e21.8 High Throughput Screening, 322\u003c\/p\u003e \u003cp\u003e21.9 Crystallization in Confined Space, 323\u003c\/p\u003e \u003cp\u003e21.10 Nonsolvent-Based Polymorph Screening, 325\u003c\/p\u003e \u003cp\u003e21.11 Polymer-Induced Heteronucleation, 325\u003c\/p\u003e \u003cp\u003e21.12 Physical Characterization, 326\u003c\/p\u003e \u003cp\u003e21.13 Thermodynamic Stability and form Selection, 327\u003c\/p\u003e \u003cp\u003eReferences, 328\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 Mixture Analysis 331\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e22.1 Introduction, 331\u003c\/p\u003e \u003cp\u003e22.2 Limitations of Wet Chemistry, 331\u003c\/p\u003e \u003cp\u003e22.3 Pharmaceutical Analysis in the Solid State, 332\u003c\/p\u003e \u003cp\u003e22.4 Measurement of Amorphous Content, 335\u003c\/p\u003e \u003cp\u003e22.5 Detection of the Degree of Crystallinity, 337\u003c\/p\u003e \u003cp\u003e22.6 Quantification of Mixtures of Polymorphs, 339\u003c\/p\u003e \u003cp\u003e22.7 Salt and Free form Composition, 340\u003c\/p\u003e \u003cp\u003e22.8 Process Analytical Technology, 342\u003c\/p\u003e \u003cp\u003eReferences, 348\u003c\/p\u003e \u003cp\u003e\u003cb\u003e23 Product Development 351\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e23.1 Chemistry, Manufacture, and Control, 351\u003c\/p\u003e \u003cp\u003e23.2 Preformulation, 353\u003c\/p\u003e \u003cp\u003e23.3 Drug Excipient Compatibility, 354\u003c\/p\u003e \u003cp\u003e23.4 Solid Dispersions, 355\u003c\/p\u003e \u003cp\u003e23.5 Abuse-Deterrent Dosage Forms, 361\u003c\/p\u003e \u003cp\u003e23.6 Drug-Eluting Stents, 363\u003c\/p\u003e \u003cp\u003e23.7 Dry Powder Inhalers (DPI), 365\u003c\/p\u003e \u003cp\u003e23.8 Lyophilization and Biopharmaceutical Products, 368\u003c\/p\u003e \u003cp\u003eReferences, 372\u003c\/p\u003e \u003cp\u003e\u003cb\u003e24 Quality by Design 375\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e24.1 Introduction, 375\u003c\/p\u003e \u003cp\u003e24.2 Quality by Design Wheel, 375\u003c\/p\u003e \u003cp\u003e24.3 Learning Before Doing, 379\u003c\/p\u003e \u003cp\u003e24.4 Risk-Based Orientation, 380\u003c\/p\u003e \u003cp\u003e24.5 API Attributes and Process Design, 381\u003c\/p\u003e \u003cp\u003e24.6 Development and Design Space, 381\u003c\/p\u003e \u003cp\u003e24.7 Process Design: Crystallization, 385\u003c\/p\u003e \u003cp\u003e24.8 Phase Transformations During Wet Granulation, 386\u003c\/p\u003e \u003cp\u003e24.9 Dissolution Tests with an IVIVC for Quality by Design, 387\u003c\/p\u003e \u003cp\u003e24.10 Conclusion, 388\u003c\/p\u003e \u003cp\u003eReferences, 388\u003c\/p\u003e \u003cp\u003eIndex 389\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":51863120478551,"sku":"9781118145302","price":145.76,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781118145302.jpg?v=1759919694","url":"https:\/\/bookcurl.com\/products\/solidstate-properties-of-pharmaceutical-materials-9781118145302","provider":"Book Curl","version":"1.0","type":"link"}